What is LNAI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LNAI?

P/E (TTM) is n/a and 52-week range is $1.08 to $13.28 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LNAI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LNAI?

The company profile lists revenue (TTM) near $30K, net income (TTM) near $-35M, EPS (TTM) near $-7.63 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Lunai Bioworks Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Los Angeles, California, US, 4.5M shares outstanding, ISIN US29350E2037 when available from company profile and filing metadata.

Lunai Bioworks Inc

$LNAI

Health Care · Biotechnology

IR Run Scenarios

$1.23

+9.82%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 29 full-time employees. The company went IPO on 2014-11-18. The company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.

Employees

Website

renovarobio.com/

IPO

2014-11-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)